Exploring Primary Immunodeficiency Disorder Treatment: A Review of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin Therapies

Program Description

Primary immunodeficiency disorders (PIDDs) consist of a wide group of disorders that lead to hindered immunity. Unlike secondary immunodeficiency disorders, which develop through factors outside of one’s own genetic makeup, PIDDs are due to errors within immune system genes. Although PIDDs typically result in increased risk to infections, other comorbidities include pulmonary disease, autoimmune conditions, autoinflammatory disorders, and malignancy. Diagnosing and treating PIDDs can be difficult, as each case can have different effects. The most common form of treatment is immunoglobulin (Ig) replacement. Ig can be given either intravenously or subcutaneously but determining which to use and how much can also be a difficult task due to factors of severity and other aspects of unique patient cases. For individuals with PIDDs to receive the best possible care, it is crucial that pharmacists play an active role in the multidisciplinary approach to treatment. This activity will enable pharmacists to develop skills in treatment through knowledge of PIDDs, from development to disease process, as well as options and regulations of treatment, contrasting intravenous and subcutaneous Ig, and opportunities to communicate with and educate both patients and other providers.

Target audience: Health-system and specialty pharmacists

Type of activity: Application
Release date: September 27, 2022
Expiration date: November 27, 2022

Time to complete activity: 1 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Discover the pathophysiology, prevalence, incidence, clinical presentation, and types of primary immunodeficiency disorders (PIDDs)
• Examine the PIDD guidelines and standard therapies used for the treatment and management of PIDDs
• Compare available intravenous immunoglobulin and subcutaneous immunoglobulin and identify how to individualize treatment
• Explore the role of the pharmacist in making patient-specific recommendations for the treatment and management of PIDDs, in counseling patients and caregivers about intravenous and subcutaneous immunoglobulin therapies, and in monitoring patients for adherence

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (1.0 CEU) under the ACPE universal activity number 0290-0000-22-374-L01-P. The activity is available for CE credit through November 27, 2022.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Elizabeth Duruz, RPh, CSP, IgCP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Michelle C. Carlson, PharmD; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms